Cargando…

Comparative Effectiveness of Persistent Use of a Name-Brand Levothyroxine (Synthroid®) vs. Persistent Use of Generic Levothyroxine on TSH Goal Achievement: A Retrospective Study Among Patients with Hypothyroidism in a Managed Care Setting

INTRODUCTION: Levothyroxine monotherapy (Synthroid® or multiple generic levothyroxine [GL] formulations) is standard treatment for hypothyroidism. Our objective was to compare effectiveness (as measured by achievement of thyroid-stimulating hormone [TSH] levels) and economic outcomes of Synthroid vs...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Liya, Chen, Yaozhu J., Grabner, Michael, Nepal, Bal, Bodhani, Amit, Espaillat, Ramon, Hennessey, James V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799578/
https://www.ncbi.nlm.nih.gov/pubmed/34905150
http://dx.doi.org/10.1007/s12325-021-01969-3
_version_ 1784642091965480960
author Wang, Liya
Chen, Yaozhu J.
Grabner, Michael
Nepal, Bal
Bodhani, Amit
Espaillat, Ramon
Hennessey, James V.
author_facet Wang, Liya
Chen, Yaozhu J.
Grabner, Michael
Nepal, Bal
Bodhani, Amit
Espaillat, Ramon
Hennessey, James V.
author_sort Wang, Liya
collection PubMed
description INTRODUCTION: Levothyroxine monotherapy (Synthroid® or multiple generic levothyroxine [GL] formulations) is standard treatment for hypothyroidism. Our objective was to compare effectiveness (as measured by achievement of thyroid-stimulating hormone [TSH] levels) and economic outcomes of Synthroid vs. any one of multiple GLs in patients with hypothyroidism. METHODS: Data for this retrospective cohort study were obtained from the HealthCore Integrated Research Database®. All study patients had ≥ 2 claims between 1 January 2006 and 31 December 2017 with ICD-9/10-CM diagnosis codes for hypothyroidism; were persistent users of Synthroid vs. any GL; and had ≥ 1 TSH laboratory result during 12-month follow-up. Patients were divided into one of two cohorts based on index medication and were 1:1 matched using propensity scores. The primary outcome was the proportion of patients with last TSH laboratory result during follow-up within the reference range (0.3–4.12 mIU/L). Secondary outcomes included all-cause and hypothyroidism-related healthcare resource utilization (HCRU) and costs. RESULTS: After propensity score matching, the Synthroid and GL cohorts each contained 18,382 patients. At follow-up, significantly more patients receiving Synthroid were in the TSH reference range vs. GL (78.5% vs. 77.2%, respectively, p =  0.002). HCRU and costs were broadly similar between the cohorts in terms of all-cause inpatient hospitalizations, emergency department visits, outpatient services, and pharmacy fills. Irrespective of index medication, patients with TSH within the reference range had significantly lower hypothyroidism-related medical and total costs compared to those outside the range. CONCLUSIONS: This real-world data study showed Synthroid was associated with better TSH target achievement vs. GL in a US managed care population. Achieving TSH goals may provide substantial economic value by reducing hypothyroidism-related HCRU and costs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01969-3.
format Online
Article
Text
id pubmed-8799578
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-87995782022-02-02 Comparative Effectiveness of Persistent Use of a Name-Brand Levothyroxine (Synthroid®) vs. Persistent Use of Generic Levothyroxine on TSH Goal Achievement: A Retrospective Study Among Patients with Hypothyroidism in a Managed Care Setting Wang, Liya Chen, Yaozhu J. Grabner, Michael Nepal, Bal Bodhani, Amit Espaillat, Ramon Hennessey, James V. Adv Ther Original Research INTRODUCTION: Levothyroxine monotherapy (Synthroid® or multiple generic levothyroxine [GL] formulations) is standard treatment for hypothyroidism. Our objective was to compare effectiveness (as measured by achievement of thyroid-stimulating hormone [TSH] levels) and economic outcomes of Synthroid vs. any one of multiple GLs in patients with hypothyroidism. METHODS: Data for this retrospective cohort study were obtained from the HealthCore Integrated Research Database®. All study patients had ≥ 2 claims between 1 January 2006 and 31 December 2017 with ICD-9/10-CM diagnosis codes for hypothyroidism; were persistent users of Synthroid vs. any GL; and had ≥ 1 TSH laboratory result during 12-month follow-up. Patients were divided into one of two cohorts based on index medication and were 1:1 matched using propensity scores. The primary outcome was the proportion of patients with last TSH laboratory result during follow-up within the reference range (0.3–4.12 mIU/L). Secondary outcomes included all-cause and hypothyroidism-related healthcare resource utilization (HCRU) and costs. RESULTS: After propensity score matching, the Synthroid and GL cohorts each contained 18,382 patients. At follow-up, significantly more patients receiving Synthroid were in the TSH reference range vs. GL (78.5% vs. 77.2%, respectively, p =  0.002). HCRU and costs were broadly similar between the cohorts in terms of all-cause inpatient hospitalizations, emergency department visits, outpatient services, and pharmacy fills. Irrespective of index medication, patients with TSH within the reference range had significantly lower hypothyroidism-related medical and total costs compared to those outside the range. CONCLUSIONS: This real-world data study showed Synthroid was associated with better TSH target achievement vs. GL in a US managed care population. Achieving TSH goals may provide substantial economic value by reducing hypothyroidism-related HCRU and costs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01969-3. Springer Healthcare 2021-12-14 2022 /pmc/articles/PMC8799578/ /pubmed/34905150 http://dx.doi.org/10.1007/s12325-021-01969-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Wang, Liya
Chen, Yaozhu J.
Grabner, Michael
Nepal, Bal
Bodhani, Amit
Espaillat, Ramon
Hennessey, James V.
Comparative Effectiveness of Persistent Use of a Name-Brand Levothyroxine (Synthroid®) vs. Persistent Use of Generic Levothyroxine on TSH Goal Achievement: A Retrospective Study Among Patients with Hypothyroidism in a Managed Care Setting
title Comparative Effectiveness of Persistent Use of a Name-Brand Levothyroxine (Synthroid®) vs. Persistent Use of Generic Levothyroxine on TSH Goal Achievement: A Retrospective Study Among Patients with Hypothyroidism in a Managed Care Setting
title_full Comparative Effectiveness of Persistent Use of a Name-Brand Levothyroxine (Synthroid®) vs. Persistent Use of Generic Levothyroxine on TSH Goal Achievement: A Retrospective Study Among Patients with Hypothyroidism in a Managed Care Setting
title_fullStr Comparative Effectiveness of Persistent Use of a Name-Brand Levothyroxine (Synthroid®) vs. Persistent Use of Generic Levothyroxine on TSH Goal Achievement: A Retrospective Study Among Patients with Hypothyroidism in a Managed Care Setting
title_full_unstemmed Comparative Effectiveness of Persistent Use of a Name-Brand Levothyroxine (Synthroid®) vs. Persistent Use of Generic Levothyroxine on TSH Goal Achievement: A Retrospective Study Among Patients with Hypothyroidism in a Managed Care Setting
title_short Comparative Effectiveness of Persistent Use of a Name-Brand Levothyroxine (Synthroid®) vs. Persistent Use of Generic Levothyroxine on TSH Goal Achievement: A Retrospective Study Among Patients with Hypothyroidism in a Managed Care Setting
title_sort comparative effectiveness of persistent use of a name-brand levothyroxine (synthroid®) vs. persistent use of generic levothyroxine on tsh goal achievement: a retrospective study among patients with hypothyroidism in a managed care setting
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799578/
https://www.ncbi.nlm.nih.gov/pubmed/34905150
http://dx.doi.org/10.1007/s12325-021-01969-3
work_keys_str_mv AT wangliya comparativeeffectivenessofpersistentuseofanamebrandlevothyroxinesynthroidvspersistentuseofgenericlevothyroxineontshgoalachievementaretrospectivestudyamongpatientswithhypothyroidisminamanagedcaresetting
AT chenyaozhuj comparativeeffectivenessofpersistentuseofanamebrandlevothyroxinesynthroidvspersistentuseofgenericlevothyroxineontshgoalachievementaretrospectivestudyamongpatientswithhypothyroidisminamanagedcaresetting
AT grabnermichael comparativeeffectivenessofpersistentuseofanamebrandlevothyroxinesynthroidvspersistentuseofgenericlevothyroxineontshgoalachievementaretrospectivestudyamongpatientswithhypothyroidisminamanagedcaresetting
AT nepalbal comparativeeffectivenessofpersistentuseofanamebrandlevothyroxinesynthroidvspersistentuseofgenericlevothyroxineontshgoalachievementaretrospectivestudyamongpatientswithhypothyroidisminamanagedcaresetting
AT bodhaniamit comparativeeffectivenessofpersistentuseofanamebrandlevothyroxinesynthroidvspersistentuseofgenericlevothyroxineontshgoalachievementaretrospectivestudyamongpatientswithhypothyroidisminamanagedcaresetting
AT espaillatramon comparativeeffectivenessofpersistentuseofanamebrandlevothyroxinesynthroidvspersistentuseofgenericlevothyroxineontshgoalachievementaretrospectivestudyamongpatientswithhypothyroidisminamanagedcaresetting
AT hennesseyjamesv comparativeeffectivenessofpersistentuseofanamebrandlevothyroxinesynthroidvspersistentuseofgenericlevothyroxineontshgoalachievementaretrospectivestudyamongpatientswithhypothyroidisminamanagedcaresetting